<SEC-DOCUMENT>0000950170-24-131712.txt : 20241129
<SEC-HEADER>0000950170-24-131712.hdr.sgml : 20241129
<ACCEPTANCE-DATETIME>20241129091559
ACCESSION NUMBER:		0000950170-24-131712
CONFORMED SUBMISSION TYPE:	144
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20241129
DATE AS OF CHANGE:		20241129

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Candel Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001841387
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				522214851
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	001-40629
		FILM NUMBER:		241513436

	BUSINESS ADDRESS:	
		STREET 1:		117 KENDRICK STREET
		STREET 2:		SUITE 450
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494
		BUSINESS PHONE:		617-916-5445

	MAIL ADDRESS:	
		STREET 1:		117 KENDRICK STREET
		STREET 2:		SUITE 450
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Candel Therapeutics, Inic.
		DATE OF NAME CHANGE:	20210120

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tak Paul Peter
		CENTRAL INDEX KEY:			0001873905
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		144

	MAIL ADDRESS:	
		STREET 1:		CANDEL THERAPEUTICS, INC.
		STREET 2:		117 KENDRICK ST SUITE 450
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494
</SEC-HEADER>
<DOCUMENT>
<TYPE>144
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<headerData>
<submissionType>144</submissionType>
<filerInfo>
<filer>
<filerCredentials>
<cik>0001873905</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>
</filerInfo>
</headerData>
<formData>
<issuerInfo>
<issuerCik>0001841387</issuerCik>
<issuerName>CANDEL THERAPEUTICS, INC.</issuerName>
<secFileNumber>001-40629</secFileNumber>
<issuerAddress>
<street1 xmlns="http://www.sec.gov/edgar/common">117 Kendrick St</street1>
<street2 xmlns="http://www.sec.gov/edgar/common">Suite 450</street2>
<city xmlns="http://www.sec.gov/edgar/common">Needham</city>
<stateOrCountry xmlns="http://www.sec.gov/edgar/common">MA</stateOrCountry>
<zipCode xmlns="http://www.sec.gov/edgar/common">02494</zipCode>
</issuerAddress>
<issuerContactPhone>617-916-5445</issuerContactPhone>
<nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Tak Paul Peter</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
<relationshipsToIssuer>
<relationshipToIssuer>Officer</relationshipToIssuer>
<relationshipToIssuer>Director</relationshipToIssuer>
</relationshipsToIssuer>
</issuerInfo>
<securitiesInformation>
<securitiesClassTitle>Common Stock</securitiesClassTitle>
<brokerOrMarketmakerDetails>
<name>Morgan Stanley Smith Barney</name>
<address>
<street1 xmlns="http://www.sec.gov/edgar/common">2000 Westchester Ave</street1>
<city xmlns="http://www.sec.gov/edgar/common">Purchase</city>
<stateOrCountry xmlns="http://www.sec.gov/edgar/common">NY</stateOrCountry>
<zipCode xmlns="http://www.sec.gov/edgar/common">10577-2530</zipCode>
</address>
</brokerOrMarketmakerDetails>
<noOfUnitsSold>44433</noOfUnitsSold>
<aggregateMarketValue>219943.35</aggregateMarketValue>
<noOfUnitsOutstanding>32475537</noOfUnitsOutstanding>
<approxSaleDate>11/29/2024</approxSaleDate>
<securitiesExchangeName>NASDAQ</securitiesExchangeName>
</securitiesInformation>
<securitiesToBeSold>
<securitiesClassTitle>Common Stock</securitiesClassTitle>
<acquiredDate>11/28/2022</acquiredDate>
<natureOfAcquisitionTransaction>RSU Award</natureOfAcquisitionTransaction>
<nameOfPersonfromWhomAcquired>Candel Therapeutics, Inc.</nameOfPersonfromWhomAcquired>
<isGiftTransaction>N</isGiftTransaction>
<amountOfSecuritiesAcquired>44433</amountOfSecuritiesAcquired>
<paymentDate>11/28/2022</paymentDate>
<natureOfPayment>Not Applicable</natureOfPayment>
</securitiesToBeSold>
<nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
<remarks>The sales reported on this Form 144 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units pursuant to the Issuer's mandatory sell to cover policy, which requires sales in an amount sufficient to cover tax withholding obligations associated with the vesting events, and the sales do not represent discretionary sales by the Reporting Person.</remarks>
<noticeSignature>
<noticeDate>11/29/2024</noticeDate>
<signature>/s/ Charles Schoch, as Attorney-in-Fact for Paul Peter Tak</signature>
</noticeSignature>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>